insights_auto
TGNA neden düştü? 2,64%?
Daha Ayrıntılı Bilgichevron_right
TGNA:FRA
Transgene SA
€0,66
arrow_downward
-2,64%(-0,018) 1G
9 Eki, 08:01:35 GMT+2 · EUR
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoTGNA ile ilgili en önemli analizler oluşturuluyor...
Açık
€0,66
Yüksek
€0,66
Düşük
€0,66
Piy. değ.
191,12 Mn
Ort. hacim
0,00
İşlem Hacmi
0,00
52 haftalık en yüksek
€1,48
52 haftalık en düşük
€0,60
HBK
-€0,17
Çalışan sayısı
160
Açık
€0,66
Yüksek
€0,66
Düşük
€0,66
Piy. değ.
191,12 Mn
Ort. hacim
0,00
İşlem Hacmi
0,00
52 haftalık en yüksek
€1,48
52 haftalık en düşük
€0,60
HBK
-€0,17
Çalışan sayısı
160
Haberler
Web kaynaklarından ve haber iş ortaklarından
Yahoo Finance
·
1 saat önce
History says midterms could hand the S&P 500 a year-end rally: Chart of the Day
Stock Titan
·
51 dakika önce
15 new hires receive stock awards from Ocular Therapeutix
Quartz
·
33 dakika önce
Nasdaq futures rise after AI stocks' worst session since August
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA hakkında